Objective: To observe the effect of slow-released morphine tablets by rectum in treating the patients of moderate to severe cancer pain with server nausea and vomiting or dysphagia. Methods: 54 cases of cancer patient...Objective: To observe the effect of slow-released morphine tablets by rectum in treating the patients of moderate to severe cancer pain with server nausea and vomiting or dysphagia. Methods: 54 cases of cancer patients with server nau- sea and vomiting symptoms or dysphagia were treated with slow-released morphine tablets by rectum, 30-90 mg/time, once every 12 hours. The drug dose was titrated by degree of pain, and the effects and adverse effects were observed. Results: The total effective rate was 81.48%, complete response rate was 51.85% (28/54), and the partial response rate was 29.63% (16/54); there were no obvious toxicities, and the common adverse symptoms included nausea (16.7%) and vomiting (9.3%). Conclusion: The treatment of slow-released morphine tablet by rectum could effectively control cancer pain, the adverse effects were slight than that by mouth. It is safe and effective to be worthy of the adhibition in clinic.展开更多
The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg)...The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg) and immediate release tablets (IRMS, 20 mg). The plasma concentration of morphine was determined by GC MS. The pharmacokinetic parameters of controlled release tablets and immediate release tablets were calculated∶ C max was 19.38±3.80 and 21.27±6.21 ng/ml, t max was 2.36 ±0.37 h and 0.56±0.16 h, t 1/2β was 3.53±0.87 and 3.03±0.74 h, AUC was 145.15±17.65 and 93.08±16.65 ng/ml, respectively. The steady state plasma concentration of morphine sulphate in cancer patients after multiple doses was achieved, C max of CRMS and IRMS was 27.43±0.33 ng/ml and 22.68±0.16 ng/ml, C min of CRMS and IRMS was 19.45±1.44 ng/ml and 18.14±0.49 ng/ml, respectively.展开更多
文摘Objective: To observe the effect of slow-released morphine tablets by rectum in treating the patients of moderate to severe cancer pain with server nausea and vomiting or dysphagia. Methods: 54 cases of cancer patients with server nau- sea and vomiting symptoms or dysphagia were treated with slow-released morphine tablets by rectum, 30-90 mg/time, once every 12 hours. The drug dose was titrated by degree of pain, and the effects and adverse effects were observed. Results: The total effective rate was 81.48%, complete response rate was 51.85% (28/54), and the partial response rate was 29.63% (16/54); there were no obvious toxicities, and the common adverse symptoms included nausea (16.7%) and vomiting (9.3%). Conclusion: The treatment of slow-released morphine tablet by rectum could effectively control cancer pain, the adverse effects were slight than that by mouth. It is safe and effective to be worthy of the adhibition in clinic.
文摘The pharmacokinetics of morphine sulphate was studied in 10 Chinese healthy volunteers after a single oral dose. Blood samples were collected before and after administration of controlled release tablets (CRMS, 30 mg) and immediate release tablets (IRMS, 20 mg). The plasma concentration of morphine was determined by GC MS. The pharmacokinetic parameters of controlled release tablets and immediate release tablets were calculated∶ C max was 19.38±3.80 and 21.27±6.21 ng/ml, t max was 2.36 ±0.37 h and 0.56±0.16 h, t 1/2β was 3.53±0.87 and 3.03±0.74 h, AUC was 145.15±17.65 and 93.08±16.65 ng/ml, respectively. The steady state plasma concentration of morphine sulphate in cancer patients after multiple doses was achieved, C max of CRMS and IRMS was 27.43±0.33 ng/ml and 22.68±0.16 ng/ml, C min of CRMS and IRMS was 19.45±1.44 ng/ml and 18.14±0.49 ng/ml, respectively.
